A Pilot Study of HIV Specific Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients With CD4+ T Cells 100-350 Cells/mm3
Data Collection
Blood-Borne Infections+11
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the body to recognize HIV more readily and increase immune response against the virus. Dendritic cells and lymphocytes are obtained from an HIV-negative sibling. HIV-specific CTLs are generated from these cells and then infused into the HIV-infected patient monthly for 6 months. Siblings must be able to donate on multiple occasions, and patients are followed every 2-4 weeks during the study. Patients are screened over 3 months prior to study entry.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria Patients must have: * HLA A2+. * Other HLA matching with sibling. * CD4 count 100-350 cells/mm3. * No active opportunistic infection or malignancy (other than cutaneous Kaposi's sarcoma). * Current stable antiviral regimen. * Normal lab values and chest x-ray. Donor siblings must have: * HLA A2+. * HIV negativity. * Good venous access. * Ability to donate on multiple occasions. * Negative status for hepatitis B and C. Exclusion Criteria Concurrent Medication: Excluded: * Immunomodulators. * Cytokines. * Systemic steroids. * IV pentamidine. * Investigational drugs.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Stanford Univ School of Medicine
Stanford, United StatesOpen Stanford Univ School of Medicine in Google Maps